Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
Meta Platforms
META
Adobe
ADBE
US Stock MarketDetailed Quotes
BRNS Barinthus Biotherapeutics
- 1.060
- 0.0000.00%
Close Dec 27 16:00 ET
- 1.060
- 0.0000.00%
Post 18:15 ET
42.64MMarket Cap-0.71P/E (TTM)
1.120High0.984Low55.12KVolume1.080Open1.060Pre Close57.99KTurnover0.20%Turnover RatioLossP/E (Static)40.23MShares4.15952wk High0.27P/B29.18MFloat Cap0.80152wk Low--Dividend TTM27.53MShs Float17.990Historical High--Div YieldTTM12.88%Amplitude0.801Historical Low1.052Avg Price1Lot Size
Barinthus Biotherapeutics News
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
Promising Clinical Trials and Potential Functional Cure Drive Buy Rating for Barinthus Biotherapeutics
Barinthus Biotherapeutics Analyst Ratings
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
Strong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B Therapies
Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $3
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics Price Target Cut to $9.50/Share From $11.00 by Alliance Global Partners
Barinthus Biotherapeutics Analyst Ratings
A. G. P. Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $9.5
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target
Buy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical Advancements
Barinthus Biotherapeutics Analyst Ratings
Barinthus Biotherapeutics Analyst Ratings
Barinthus Biotherapeutics Analyst Ratings
Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Barinthus Biotherapeutics (BRNS) and GoodRx Holdings (GDRX)
Barinthus Biotherapeutics Analyst Ratings
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.